Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CHRNG | P07510 | 1/20 | 0.46 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRND | Q07001 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7305175 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL105590 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL4808799 | 0.81 | CHRNB2 (0.51) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| Formaldehyde SCHEMBL28730871 | 0.80 | CHRNB2 (0.47) | CHRNB2CHRNA4MAPTRAB9ANPSR1 | |
| SCHEMBL14351334 | 0.78 | CHRNB2 (0.49) | CHRNB2CHRNA4MAPTRAB9ANPSR1 | |
| SCHEMBL11478353 | 0.78 | CHRNB2 (0.49) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL5570294 | 0.77 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNA1 | |
| SCHEMBL7864774 | 0.75 | SMN1; SMN2 (0.41) | RAB9ANPSR1LMNA | |
| SCHEMBL24458 | 0.74 | KCNA3 (0.50) | CHRNB2CHRNA4CHRNA3CHRNA7CHRNB4 | |
| SCHEMBL3266596 | 0.74 | CHRNB2 (0.62) | CHRNB2CHRNA4MAPTRAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| EP-2130828-A1 | SULFONAMIDE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1301480-B1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LAB (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20050113435-A1 | Histamine-3 receptor ligands for diabetic conditions | HANCOCK ARTHUR A (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1474132-A1 | HISTAMINE-3 RECEPTOR LIGANDS FOR DIABETIC CONDITIONS | Abbott Laboratories (US) | 2004-11-10 | — | — | EP | disclosed |
| EP-1467727-A1 | 1,3-DISUBSTITUTED AND 1,3,3,-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6620839-B2 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES | 2003-09-16 | — | — | US | disclosed |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | ABBOTT LABORATORIES | 2003-08-14 | — | — | US | disclosed |
| WO-2003059342-A1 | HISTAMINE-3 RECEPTOR LIGANDS FOR DIABETIC CONDITIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| US-4908444-A | Method of producing cephem compounds | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-03-13 | — | — | US | disclosed |
| EP-0354538-A2 | Method for producing cephem compounds | Takeda Chemical Industries, Ltd. (JP) | 1990-02-14 | — | — | EP | disclosed |
| EP-0230972-A2 | Method of producing cephem compounds | Takeda Chemical Industries, Ltd. (JP) | 1987-08-05 | — | — | EP | disclosed |
| US-4680390-A | CEPHALOSPORINS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-07-14 | — | — | US | disclosed |
| US-4520194-A | BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-05-28 | — | — | US | disclosed |
| US-4510138-A | 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]cephalosporin derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-04-09 | — | — | US | disclosed |
| US-4278671-A | ANTIBIOTICS, BACTERICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1981-07-14 | — | — | US | disclosed |
| US-4182866-A | CEPHALOSPORINS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1980-01-08 | — | — | US | disclosed |
| US-4145540-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1979-03-20 | — | — | US | disclosed |
| US-4011214-A | 3-(MORPHOLINOALKOXYIMINOMETHYL)CEPHEM COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | HRH4, HRH2, HRH3 | CHRNB2 1168/4885CHRNA4 624/4885MAPT 3813/4885 |
| US-20050113435-A1 | Histamine-3 receptor ligands for diabetic conditions | HRH4, HRH2, HRH3 | CHRNB2 1168/4885CHRNA4 624/4885MAPT 3813/4885 |
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | CHRNB2 2740/4885CHRNA4 3061/4885MAPT 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.